AC   CVCL_3153
SY   RERF-LCMA; LC-MA; LCMA; Radiation Effects Research Foundation-Lung Cancer-MA; Matsushima
DR   BioSample; SAMN03151921
DR   BioSample; SAMN03472512
DR   Cell_Model_Passport; SIDM01152
DR   Cosmic; 713883
DR   Cosmic; 801613
DR   Cosmic; 876160
DR   Cosmic; 929152
DR   GEO; GSM827581
DR   IARC_TP53; 2386
DR   Progenetix; CVCL_3153
DR   Wikidata; Q54949771
RX   PubMed=9290701;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=20215515;
RX   PubMed=23136038;
CC   Problematic cell line: Contaminated. Shown to be a SK-MES-1 derivative (PubMed=23136038). Originally thought to originate from a small cell lung carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00386.
CC   Population: Caucasian.
CC   Doubling time: ~1.5 days (lot 01252008) (JCRB).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Homozygous (PubMed=10536175).
CC   Omics: SNP array analysis.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 13,14
ST   D5S818: 11
ST   D7S820: 8
ST   TH01: 6,10
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0630 ! SK-MES-1
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 25
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=23136038; DOI=10.1002/ijc.27931;
RA   Capes-Davis A., Reid Y.A., Kline M.C., Storts D.R., Strauss E.,
RA   Dirks W.G., Drexler H.G., MacLeod R.A.F., Sykes G., Kohara A.,
RA   Nakamura Y., Elmore E., Nims R.W., Alston-Roberts C., Barallon R.,
RA   Los G.V., Nardone R.M., Price P.J., Steuer A., Thomson J.A.,
RA   Masters J.R.W., Kerrigan L.;
RT   "Match criteria for human cell line authentication: where do we draw
RT   the line?";
RL   Int. J. Cancer 132:2510-2519(2013).